anovulatory infertility
Women's health · 2012–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| human menopausal gonadotrophin Assisted reproductive technology (IVF/ET, GIFT, ICSI) and anovulatory infertility including polycystic ovarian disease unresponsive to clomiphene citrate. | Jul 2022 | Recommended | none received |
| follitropin alfa Treatment of anovulatory infertility in women unresponsive to clomiphene citrate, controlled ovarian hyperstimulation in women undergoing assisted reproductive… | Jul 2021 | Recommended with restriction | input received IVF Directors Group |
| chorionic gonadotrophin Treatment of anovulatory infertility, infertility due to hypogonadotrophic hypogonadism or isolated luteinising hormone deficiency, combined deficiency of… | Mar 2017 | Recommended | none received |
| human menopausal gonadotrophin Treatment of anovulatory infertility in women who have failed to ovulate or conceive on clomiphene citrate and/or gonadorelin. | Mar 2016 | Not recommended | none received |
| gonadotrophin-menopausal human Anovulatory infertility in women who have failed to conceive with clomiphene citrate and/or gonadorelin. | Nov 2016 | Not recommended | input received |
| human menopausal gonadotrophin Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART), including IVF/ET, GIFT, and… | Mar 2012 | Recommended with restriction | unclear |
Who spoke
IVF Directors Group
What the PBS pays
$140M in government benefit over 2024–25, across 95,985 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| follitropin alfa | $113M |
| human menopausal gonadotrophin | $27.4M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| follitropin betaPUREGON follitropin beta (rch) 300 IU solution for injection cartridge | 2001 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.